British biotech chief quits following failed merger

摘要

British Biotech is looking for a new leader after Elliot Glodstein agreed to step down after just four years as chief executive. Difficulty in developing successful new products and the company's inability to find a merger partner undermined the company's share price and, ultimately, Goldstein's own position there.